Serum IgE levels and the expression of low affinity receptor for IgE ( @entity7527 / @entity7527 ) are increased in @entity4536 . The ligation of @entity7527 receptor by IgE-anti-IgE immune complexes results in @entity842 (NO) production, which is a critical leishmanicidal factor. @entity1 monocytes/macrophages express @entity7527 / @entity7527 after activation with @entity379 and @entity3646 . In the present study, we assessed the relationship between NO, total and Leishmania-specific IgE and soluble @entity7527 across the clinical spectrum of @entity4536 ( @entity4536 ). Sixty-nine @entity4536 @entity1 and 22 endemic controls were studied. NO concentration was estimated using the Greiss method. Soluble @entity7527 , total IgE and anti-Leishmania IgE levels were measured using ELISA. Soluble @entity7527 was increased in the four @entity1 groups (0.001<P<0.05) compared by the Mann-Whitney test to healthy subjects, particularly in @entity17566 ( @entity17566 ) and @entity21700 ( @entity21700 ) @entity1 . Total IgE levels were higher in @entity4536 @entity1 (P<0.0001). Anti-Leishmania IgE showed a similar tendency, where @entity17566 and @entity21700 @entity1 had greater levels. All @entity1 groups, except @entity4536 ( @entity4536 ) @entity1 , showed elevated levels of @entity6836 /NO(3)(-) compared to healthy individuals (0.001<P<0.01). Interestingly, @entity4536 @entity1 did not produce significant levels of @entity6836 / @entity8326 . @entity4536 @entity1 showed a significant positive correlation between soluble @entity7527 and anti-Leishmania IgE. @entity21700 @entity1 showed a positive correlation between both parameters. Overall results suggest that sCD23, IgE and NO may play different roles across the @entity4536 spectrum.

Variations in the serum levels of soluble @entity7527 , XXXX and IgE across the spectrum of @entity4536 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Human'] @entity8326 :: ('CHEBI:29794', 'Chemical') :: ['NO(3)(-)'] @entity21700 :: ('MESH:D016774', 'Disease') :: ['diffuse cutaneous leishmaniasis', 'DCL'] @entity4536 :: ('MESH:D016773', 'Disease') :: ['ACL', 'American cutaneous leishmaniasis', 'ICL', 'cutaneous leishmaniasis', 'intermediate or chronic cutaneous leishmaniasis'] @entity379 :: ('3458', 'Gene') :: ['IFN-gamma'] @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide'] @entity17566 :: ('MESH:D007897', 'Disease') :: ['MCL', 'mucocutaneous leishmaniasis'] @entity7527 :: ('2208', 'Gene') :: ['Fc epsilon RII', 'CD23'] @entity6836 :: ('CHEBI:29785', 'Chemical') :: ['NO(2)(-)'] @entity3646 :: ('3565', 'Gene') :: ['IL-4']
@entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']
